Giovannoni G, Rammohan K, Cook S, et al. Proportions of patients with highly active RMS achieving no evidence of disease activity (NEDA) in response to cladribine tablets in CLARITY. ECTRIMS 217, P1143.
Extra voordeel langere dosisinterval natalizumab: minder JCV-conversie
mei 2025 | Multipele Sclerose